Quince Therapeutics, Inc.
$ 3.60
2.27%
04 Dec - close price
- Market Cap 200,453,000 USD
- Current Price $ 3.60
- High / Low $ 3.72 / 3.52
- Stock P/E N/A
- Book Value 0.02
- EPS -1.20
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -2.48 %
- 52 Week High 3.73
- 52 Week Low 0.72
About
Quince Therapeutics, Inc. is a cutting-edge biopharmaceutical company based in South San Francisco, California, focused on developing precision therapies for rare and debilitating diseases. By employing advanced therapeutic platforms and innovative research methodologies, Quince addresses critical unmet medical needs aimed at enhancing patient quality of life through its diverse and promising pipeline. As it pursues its mission to improve patient outcomes globally, the company is strategically positioned for growth and is set to make substantial contributions to the healthcare landscape.
Analyst Target Price
$7.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-11 | 2025-05-12 | 2025-03-31 | 2024-11-12 | 2024-08-13 | 2024-04-01 | 2024-02-14 | 2023-11-14 | 2023-08-03 | 2023-05-15 | 2023-03-15 |
| Reported EPS | -0.25 | -0.34 | -0.34 | -0.2839 | -0.1272 | -0.6434 | -0.2171 | -0.22 | -0.1483 | -0.136 | -0.3418 | -0.15 |
| Estimated EPS | -0.22 | -0.26 | -0.23 | -0.1 | -0.1 | None | None | -0.28 | None | 0 | -0.3092 | -0.2876 |
| Surprise | -0.03 | -0.08 | -0.11 | -0.1839 | -0.0272 | 0 | 0 | 0.06 | 0 | -0.136 | -0.0326 | 0.1376 |
| Surprise Percentage | -13.6364% | -30.7692% | -47.8261% | -183.9% | -27.2% | None% | None% | 21.4286% | None% | None% | -10.5433% | 47.8442% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.1833 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QNCX
2025-10-17 20:15:00
Quince Therapeutics issued an update regarding a statement in their Investor Day presentation concerning IntraBio's Phase 2 study. The company removed an incorrect statement suggesting failed efficacy in ataxia-telangiectasia, clarifying that the statement was based on a different single-site study and not the IntraBio study. Investors are advised not to rely on the removed information.
2023-12-31 23:59:59
Quince Therapeutics has successfully acquired EryDel S.p.A., gaining EryDex, a Phase 3 lead asset targeting the rare neurodegenerative disease Ataxia-Telangiectasia (A-T). This acquisition enhances Quince's rare disease pipeline with an innovative drug delivery technology and a potential $1+ billion market opportunity. The company plans to initiate a pivotal Phase 3 clinical trial in Q2 2024, aiming for an NDA submission after this single study, and structured the acquisition with a stock-for-stock exchange and potential milestone payments.
2023-11-06 15:30:11
Wilson Sonsini advised Quince Therapeutics on patent matters related to its recent acquisition of EryDel S.p.A. Quince Therapeutics completed the acquisition of EryDel, a late-stage biotech company, on October 23, 2023. The acquisition, valued with potential downstream payments of up to $485 million, secures EryDel's lead asset, EryDex, aimed at treating the rare neurodegenerative disease Ataxia-Telangiectasia.
2023-02-01 15:30:11
Evelo Biosciences, Inovio, and Quince Therapeutics announced layoffs to extend their cash runways, adding to over 100 drugmakers cutting costs since last year. These workforce reductions reflect a sector-wide retrenchment driven by clinical setbacks, strategic shifts, and difficulties in raising capital. Evelo's layoffs follow a failed Phase 2 trial, while Quince is reducing staff by 47% as it shifts its focus to rare disease drugs, and Inovio continues to struggle after its delayed COVID-19 vaccine efforts.
2022-08-02 18:16:43
Quince Therapeutics' investigational oral small molecule, COR588, for mild to moderate Alzheimer’s disease has been deemed safe and well-tolerated in a recently completed Phase 1 trial. This second-generation gingipain inhibitor, designed for once-daily dosing, exhibited no serious side effects in healthy adults and efficiently penetrated the central nervous system. This development follows a full hold on the clinical program for its predecessor, COR388, and the company is set to provide an update on the COR588 clinical program soon.
2022-07-27 08:01:00
Cortexyme, Inc. announced its corporate name change to Quince Therapeutics will take effect on Monday, August 1, 2022. Concurrently, the company's ticker symbol on the Nasdaq Global Select Market will change from "CRTX" to "QNCX". The company plans to issue a news release detailing its go-forward growth strategy and development pipeline plans, and will launch a new corporate website and social media presence.
